The Prostate Cancer Foundation has welcomed a decision by New Zealand's drug-buying agency Pharmac to subsidise two new treatments for prostate disease.
Pharmac will fund the drug finasteride, sold as Fintral, for enlarged prostates, from Wednesday.
It will also fund bicalutamide, sold as Bicalox, for advanced prostate cancer, from November.
The foundation says not all men can afford to pay $500 a month for bicalutamide, and access to the medication should improve their quality of life.
Pharmac says increasing treatment options is a step forward for patients and doctors.